Table 3

Associations between clinical factors and RASSF1A or TSP-1 methylation status

CharacteristicRASSF1ATSP-1
Methylated n (%)Unmethylated n (%)TotalPMethylated n (%)Unmethylated n (%)TotalP
Age0.010.84
 ≥126 (83.9)5 (16.1)3118 (58.1)13 (41.9)31
 <113 (52.0)12 (48.0)2513 (54.2)11 (45.8)24
Stage0.140.44
 1, 2, 3, 4s20 (60.6)13 (39.4)3320 (60.6)13 (39.4)33
 419 (82.6)4 (17.4)2311 (50.0)11 (50.0)22
 GNR0 (0)4 (100)53 (60)2 (40)5
Risk-group0.0160.68
 Nonhigh-risk21 (58.3)15 (41.7)3619 (54.3)16 (45.7)35
 High-risk18 (90.0)2 (10.0)2012 (60.0)8 (40.0)20
MYCN 0.110.76
 Non-Amp25 (62.5)15 (37.5)4022 (55.0)18 (45.0)40
 Amp14 (87.5)2 (12.5)169 (60.0)6 (40.0)15
Survival<0.0010.88
 Dead19 (95.0)1 (5.0)2012 (60.0)8 (40.0)20
 Alive20 (55.6)16 (44.4)3619 (54.3)16 (45.7)35
RASSF1A 0.73
 Unmethylated9 (52.9)8 (47.1)17
 Methylated22 (57.9)16 (42.1)38
TSP-1 0.73
 Unmethylated16 (66.7)8 (33.3)24
 Methylated22 (71.0)9 (29.0)31
  • Abbreviation: GNR, ganglioneuroma.